Dr Lorenz M. Mayr

Vice President & Global Head, Biological reagents & Assay Development, AstraZeneca plc (UK/Sweden)

Dr Mayr worked with Prof Peter Kim at the MIT in Cambridge, USA, before joining the Central Research and later the Pharma Research Departments at Bayer Pharma AG in Leverkusen and Wuppertal, where he was appointed Leader for target nomination, assay development and screening for human disease areas. In 2001, Dr Mayr was recruited by Novartis Pharma AG as Technology Program Head for novel assay technologies, building up a process group specializing in industrialized modern lead discovery. In 2005 Dr Mayr was appointed Executive Director, Head BioChemical Screening, at the Novartis Lead Discovery Center (LDC) directing high-throughput screening for all biochemical assays at the Novartis Lead Finding Platform in Basel/Switzerland. In 2007, Dr Mayr was appointed Head of the Biology Unit at the Protease Platform, Center of Proteomic Chemistry (CPC), at the Novartis NIBR. In September 2012, Dr. Mayr has joined AstraZeneca as Vice President & Global Head, Biological reagents & Assay Development.

He has published more than 50 papers in peer-reviewed journals and acts on the Editorial Board of 8 scientific journals, including his role as Associate Editor for the Journal of Biomolecular Screening. He is also the Conference Chair of MipTec, Europe’s largest drug discovery conference with more than 3’000 attendees every year.

Dr Mayr will add the perspective of a globally operating large Pharma organization to the IAB.